ONC vs. OPTI, RLM, NSCI, HEMO, IXI, OBD, BVX, FAB, CIZ, and APTA
Should you be buying Oncimmune stock or one of its competitors? The main competitors of Oncimmune include OptiBiotix Health (OPTI), Realm Therapeutics (RLM), NetScientific (NSCI), Hemogenyx Pharmaceuticals (HEMO), IXICO (IXI), Oxford BioDynamics (OBD), BiVictriX Therapeutics (BVX), Fusion Antibodies (FAB), Cizzle Biotechnology (CIZ), and Aptamer Group (APTA). These companies are all part of the "biotechnology" industry.
Oncimmune vs.
Oncimmune (LON:ONC) and OptiBiotix Health (LON:OPTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
Oncimmune has higher revenue and earnings than OptiBiotix Health. OptiBiotix Health is trading at a lower price-to-earnings ratio than Oncimmune, indicating that it is currently the more affordable of the two stocks.
In the previous week, Oncimmune had 1 more articles in the media than OptiBiotix Health. MarketBeat recorded 1 mentions for Oncimmune and 0 mentions for OptiBiotix Health. OptiBiotix Health's average media sentiment score of 0.00 beat Oncimmune's score of -0.45 indicating that OptiBiotix Health is being referred to more favorably in the news media.
Oncimmune has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, OptiBiotix Health has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.
OptiBiotix Health received 77 more outperform votes than Oncimmune when rated by MarketBeat users. Likewise, 59.18% of users gave OptiBiotix Health an outperform vote while only 59.13% of users gave Oncimmune an outperform vote.
25.0% of Oncimmune shares are held by institutional investors. Comparatively, 4.9% of OptiBiotix Health shares are held by institutional investors. 31.0% of Oncimmune shares are held by company insiders. Comparatively, 12.0% of OptiBiotix Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Oncimmune has a net margin of 581.63% compared to OptiBiotix Health's net margin of -524.43%. OptiBiotix Health's return on equity of -36.76% beat Oncimmune's return on equity.
Summary
Oncimmune beats OptiBiotix Health on 8 of the 15 factors compared between the two stocks.
Get Oncimmune News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oncimmune Competitors List
Related Companies and Tools
This page (LON:ONC) was last updated on 2/22/2025 by MarketBeat.com Staff
